Olanzapine in pediatric chemotherapy induced nausea and vomiting i

Phase 3

• Conditions: Chemotherapy induced nausea and vomiting.

• Registration Number: IRCT20120415009475N14
• Lead Sponsor: Vice Chancellor for research of Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Pediatric patients undergoing chemotherapy with medications inducing moderate to severe nausea

Exclusion Criteria

Heart failure or heart disease associated with the risk of Arrhythmia.
Epilepsy
Kidney failure
Liver failure
Mechanical ventilation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Occurrence of nausea and vomiting. Timepoint: Daily for 7 days. Method of measurement: Questionare.

Secondary Outcome Measures

Name	Time	Method
Oral intake tolerance. Timepoint: Daily for 7 days. Method of measurement: Questionare.;Weight loss. Timepoint: Daily for 7 days. Method of measurement: Weighing.